Online citations, reference lists, and bibliographies.
← Back to Search

Chitosan Grafted-poly(ethylene Glycol) Methacrylate Nanoparticles As Carrier For Controlled Release Of Bevacizumab.

Corina-Lenuța Savin, M. Popa, C. Delaite, M. Costuleanu, D. Costin, C. Peptu
Published 2019 · Materials Science, Medicine

Save to my Library
Download PDF
Analyze on Scholarcy
Share
The aim of the present study is to obtain, for the first time, polymeric nanocarriers based on the chitosan grafted-poly(ethylene glycol) methacrylate derivative. The strategy involves the use of chitosan grafted-poly(ethylene glycol) methacrylate with high solubility in water, obtained via Michael addition, in order to prepare potentially non-toxic micro/nanoparticles (MNPs). By modifying chitosan, its solubility in aqueous media was improved. Micro/nanoparticles-based chitosan grafted-poly(ethylene glycol) methacrylate were obtained under mild condition, with good and controlled swelling properties in acetate buffer solution (ABS) and phosphate buffer solution (PBS). The technique selected for the preparation of the MNPs was a double crosslinking (ionic and covalent) process in reverse emulsion which provide the mechanical stability of the polymeric nanocarrier. The chitosan derivative and MNPs were thoroughly characterized by Fourier Transform Infrared Spectroscopy (FT-IR), Thermogravimetric Analysis (TGA), Differential Scanning Calorimetry (DSC), Scanning Electron Microscopy (SEM). The Scanning Electron Microscopy photographs revealed that prepared MNPs have different diameters depending on the used stirring rate and polymer concentration. Nanoparticles potential as drug delivery system was analyzed by loading bevacizumab (BEV) a full-length monoclonal antibody. Also, the prepared particles were found suitable from the cytotoxicity and hemocompatibility point of view enabling their potential use as delivery system for the treatment of posterior segment of the eye conditions.
This paper references
10.1016/j.ijbiomac.2014.10.052
Chitosan-based nanoparticles for tumor-targeted drug delivery.
M. Prabaharan (2015)
10.1016/J.CCLET.2014.06.027
Preparation and characterization of mPEG grafted chitosan micelles as 5-fluorouracil carriers for effective anti-tumor activity
Dong-Jun Fu (2014)
10.1016/J.PROGPOLYMSCI.2011.10.001
PEGylated chitosan derivatives: synthesis, characterizations and pharmaceutical applications
L. Casettari (2012)
10.1634/theoncologist.2009-0121
FDA drug approval summary: bevacizumab (Avastin) as treatment of recurrent glioblastoma multiforme.
M. Cohen (2009)
10.1016/B978-0-444-63774-1.00010-7
Chemically Modified Polysaccharides With Applications in Nanomedicine
J. Desbrières (2018)
10.1016/S0142-9612(99)00048-4
Self-curing membranes of chitosan/PAA IPNs obtained by radical polymerization: preparation, characterization and interpolymer complexation.
C. Peniche (1999)
10.1007/s11095-008-9713-1
Intracellular Delivery of Heparin Complexed with Chitosan-g-Poly(Ethylene Glycol) for Inducing Apoptosis
K. H. Bae (2008)
10.1002/jbm.a.34591
Hematotoxicological analysis of surface-modified and -unmodified chitosan nanoparticles.
Ragima Nadesh (2013)
10.1016/J.COLSURFB.2007.07.012
Self-aggregated nanoparticles from methoxy poly(ethylene glycol)-modified chitosan: synthesis; characterization; aggregation and methotrexate release in vitro.
X. Yang (2008)
10.1163/156856209X444330
In Vivo Validation of Biological Responses of bFGF Released from Microspheres Formulated by Blending Poly-Lactide-co-Glycolide and Poly(ethylene glycol)-Grafted-Chitosan in Hamster Cheek Pouch Microcirculatory Models
Christine A. Falabella (2009)
Drug delivery for posterior segment eye disease.
D. Geroski (2000)
10.1007/S00396-011-2437-5
Polyelectrolyte complexes of chitosan/heparin and N,N,N-trimethyl chitosan/heparin obtained at different pH: I. Preparation, characterization, and controlled release of heparin
Alessandro F. Martins (2011)
[Novel approach for management of age-related macular degeneration--antiangiogenic therapy and retinal regenerative therapy].
Y. Tamaki (2007)
10.1089/jop.2010.0158
Comparison of long-acting bevacizumab formulations in the treatment of choroidal neovascularization in a rat model.
C. K. Pan (2011)
10.1021/BC050217O
Development and brain delivery of chitosan-PEG nanoparticles functionalized with the monoclonal antibody OX26.
Y. Aktaş (2005)
10.1016/J.EJPB.2007.08.009
Nasal absorption enhancement of insulin using PEG-grafted chitosan nanoparticles.
X. Zhang (2008)
10.2174/1381612821666151027151847
Modern drug delivery systems for targeting the posterior segment of the eye.
C. Peptu (2015)
10.1016/j.ejpb.2016.10.009
Lipid nanoparticles (SLN, NLC): Overcoming the anatomical and physiological barriers of the eye – Part I – Barriers and determining factors in ocular delivery
E. Sánchez-López (2017)
10.1634/THEONCOLOGIST.12-6-713
FDA drug approval summary: bevacizumab (Avastin) plus Carboplatin and Paclitaxel as first-line treatment of advanced/metastatic recurrent nonsquamous non-small cell lung cancer.
M. Cohen (2007)
10.1007/s11671-009-9427-2
Self-Assembled Polymeric Micellar Nanoparticles as Nanocarriers for Poorly Soluble Anticancer Drug Ethaselen
Xinru Li (2009)
10.1016/J.CARBPOL.2010.07.057
Electrospinning of methoxy poly(ethylene glycol)-grafted chitosan and poly(ethylene oxide) blend aqueous solution
J. Han (2011)
10.1097/00006982-200603000-00001
TESTING INTRAVITREAL TOXICITY OF BEVACIZUMAB (AVASTIN)
Roberta P A Manzano (2006)
10.1016/j.ijbiomac.2016.02.063
Preparation and cytotoxicity of N-modified chitosan nanoparticles applied in curcumin delivery.
S. P. Facchi (2016)
10.1016/S0014-3057(03)00068-5
Synthesis and characterization of water-soluble O-succinyl-chitosan
C. Zhang (2003)
10.1016/S0021-5155(99)00092-1
Experimental uveitis induced by intravitreal or intravenous lipoteichoic acid in rabbits.
J. Chen (1999)
10.1016/0378-5173(89)90306-2
A simple equation for the description of solute release. III. Coupling of diffusion and relaxation
N. Peppas (1989)
10.1007/s10456-013-9398-x
In vitro and ex vivo retina angiogenesis assays
S. Rezzola (2013)
10.1177/0883911509350262
Double Cross-linked Chitosan—Gelatin Particulate Systems for Ophthalmic Applications
C. Peptu (2010)
10.1097/IAE.0b013e3181a2f42a
PREPARATION, CHARACTERIZATION, AND IN VIVO EVALUATION OF NANOLIPOSOMES-ENCAPSULATED BEVACIZUMAB (AVASTIN) FOR INTRAVITREAL ADMINISTRATION
M. Abrishami (2009)
10.1021/nl0805615
Method for analysis of nanoparticle hemolytic properties in vitro.
M. Dobrovolskaia (2008)
10.2174/1874364101206010054
Controlled Release of Bevacizumab Through Nanospheres for Extended Treatment of Age-Related Macular Degeneration
Fengfu Li (2012)
10.1016/0168-3659(87)90035-6
A simple equation for description of solute release II. Fickian and anomalous release from swellable devices
P. L. Ritger (1987)
10.1016/j.ijbiomac.2016.07.058
New hybrid magnetic nanoparticles based on chitosan-maltose derivative for antitumor drug delivery.
Liana Alupei (2016)
10.1016/0168-3659(87)90034-4
A simple equation for description of solute release I. Fickian and non-fickian release from non-swellable devices in the form of slabs, spheres, cylinders or discs
P. L. Ritger (1987)
10.1007/s10856-008-3500-8
PEG-grafted chitosan nanoparticles as an injectable carrier for sustained protein release
X. Zhang (2008)
10.3980/j.issn.2222-3959.2014.02.08
Establishing an experimental rat model of photodynamically-induced retinal vein occlusion using erythrosin B.
W. Chen (2014)
10.1016/J.AJO.2006.03.058
Absence of histologic retinal toxicity of intravitreal bevacizumab in a rabbit model.
S. Bakri (2006)
10.1155/2014/951942
Investigations on Agglomeration and Haemocompatibility of Vitamin E TPGS Surface Modified Berberine Chloride Nanoparticles
P. R. Vuddanda (2014)
10.1016/S0032-3861(97)10020-9
Aggregation phenomenon of PEG-grafted chitosan in aqueous solution
T. Ouchi (1998)
10.1163/156856207794761943
Investigation on the properties of methoxy poly(ethylene glycol)/chitosan graft co-polymers
L. Deng (2007)
10.1016/j.jconrel.2014.05.031
Nanotherapy for posterior eye diseases.
I. P. Kaur (2014)
10.1016/J.CARBPOL.2004.06.033
Physicochemical properties and blood compatibility of acylated chitosan nanoparticles
D. Lee (2004)
10.1016/j.ijbiomac.2009.08.007
Photo-polymeriable chitosan derivative prepared by Michael reaction of chitosan and polyethylene glycol diacrylate (PEGDA).
Guiping Ma (2009)
10.1016/J.IJPHARM.2006.10.004
Phase transition water-in-oil microemulsions as ocular drug delivery systems: in vitro and in vivo evaluation.
Judy Chan (2007)
10.1016/0039-6257(92)90003-C
Systemic antiviral drugs used in ophthalmology.
S. Teich (1992)
10.1038/nrd1381
Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer
N. Ferrara (2004)
10.1590/0104-6632.20160332S20140074
STABILITY IMPROVEMENT OF IMMOBILIZED ALKALINE PHOSPHATASE USING CHITOSAN NANOPARTICLES
F. Jafary (2016)
10.1136/bjo.2006.094995
Effects of bevacizumab on retinal function in isolated vertebrate retina
M. Lueke (2006)
10.1016/j.ijpharm.2012.06.029
Double crosslinked interpenetrated network in nanoparticle form for drug targeting--preparation, characterization and biodistribution studies.
Anca N Jătariu Cadinoiu (2012)
10.1016/J.CIS.2004.02.003
Preparation of metal nanoparticles in water-in-oil (w/o) microemulsions.
I. Capek (2004)
The use of animal models in the study of diabetes mellitus.
A. Chatzigeorgiou (2009)
10.1097/00006982-200603000-00002
ELECTROPHYSIOLOGIC AND RETINAL PENETRATION STUDIES FOLLOWING INTRAVITREAL INJECTION OF BEVACIZUMAB (AVASTIN)
Jonathan Shahar (2006)
10.1016/j.ijpharm.2012.04.004
Chitosan-g-PEG nanoparticles ionically crosslinked with poly(glutamic acid) and tripolyphosphate as protein delivery systems.
S. Papadimitriou (2012)



This paper is referenced by
10.3390/molecules24101960
Chitosan-Based (Nano)Materials for Novel Biomedical Applications
G. Kravanja (2019)
10.1016/j.ijpharm.2019.118767
Intravitreal anti-VEGF drug delivery systems for age-related macular degeneration.
Andrea Luaces-Rodríguez (2019)
10.3389/fbioe.2020.00004
Stable Chitosan-Based Nanoparticles Using Polyphosphoric Acid or Hexametaphosphate for Tandem Ionotropic/Covalent Crosslinking and Subsequent Investigation as Novel Vehicles for Drug Delivery
Ramzi Mukred Saeed (2020)
10.1016/j.eurpolymj.2020.109821
Zwitterionic choline phosphate functionalized chitosan with antibacterial property and superior water solubility
Min Lu (2020)
10.1007/s12247-020-09465-x
A Comparative Study of Levocetirizine Loaded Vesicular and Matrix Type System for Topical Application: Appraisal of Therapeutic Potential against Atopic Dermatitis
Ravi Raj Pal (2020)
10.3390/app9183899
Polymers and Polymer Nanocomposites for Cancer Therapy
D. Feldman (2019)
10.1016/j.msec.2020.111351
Co-regulative effects of chitosan-fennel seed extract system on the hormonal and biochemical factors involved in the polycystic ovarian syndrome.
A. Bayrami (2020)
10.1016/j.ijbiomac.2020.02.196
Advancement on modification of chitosan biopolymer and its potential applications.
N. Negm (2020)
10.1016/j.msec.2020.111398
Novel hybrid lipid nanocapsules loaded with a therapeutic monoclonal antibody –Bevacizumab– and Triamcinolone acetonide for combined therapy in neovascular ocular pathologies
María Lina Formica (2021)
10.1016/j.ijbiomac.2020.05.207
New formulations based on salicyl-imine-chitosan hydrogels for prolonged drug release.
Manuela-Maria Iftime (2020)
10.3390/polym12071519
Chitosan and its Derivatives for Ocular Delivery Formulations: Recent Advances and Developments
Alexandra Zamboulis (2020)
Semantic Scholar Logo Some data provided by SemanticScholar